

Sani Haider Kizilbash

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1709605/publications.pdf>

Version: 2024-02-01

41
papers

1,073
citations

759233

12
h-index

454955

30
g-index

41
all docs

41
docs citations

41
times ranked

2023
citing authors

#	ARTICLE	IF	CITATIONS
1	Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. <i>Neuro-Oncology</i> , 2018, 20, 184-191.	1.2	443
2	Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv369.	6.3	102
3	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2735-2743.	4.1	75
4	Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts. <i>Clinical Cancer Research</i> , 2014, 20, 3730-3741.	7.0	64
5	PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. <i>Frontiers in Oncology</i> , 2018, 8, 670.	2.8	60
6	Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2735-2746.	4.1	58
7	Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. <i>Pharmaceutical Research</i> , 2018, 35, 177.	3.5	53
8	Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1383-1395.	0.8	31
9	The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2014, 120, 85-93.	2.9	30
10	Central nervous system prophylaxis in diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2016, 97, 108-120.	2.2	27
11	Seizures in patients with primary brain tumors: what is their psychosocial impact?. <i>Journal of Neuro-Oncology</i> , 2016, 128, 285-291.	2.9	22
12	A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS350-TPS350.	1.6	15
13	The role of radiation and chemotherapy in adult patients with high-grade brainstem gliomas: results from the National Cancer Database. <i>Journal of Neuro-Oncology</i> , 2020, 146, 303-310.	2.9	13
14	Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 355-363.	2.4	13
15	Incidence, Characteristics, and Implications of Seizures in Patients With Glioblastoma. <i>American Journal of Hospice and Palliative Medicine</i> , 2017, 34, 650-653.	1.4	10
16	Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance) Tj ETQq0 0 0 rgBT1/0 Overlock 10 Tf 50 1		
17	Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal. <i>Frontiers in Oncology</i> , 2019, 9, 1216.	2.8	9
18	A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2075-TPS2075.	1.6	9

#	ARTICLE	IF	CITATIONS
19	New therapeutic agents for diabetic kidney disease. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 553-575.	0.2	4
20	Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens. <i>International Journal of Clinical Practice</i> , 2014, 68, 578-589.	1.7	4
21	Glioblastoma with bilateral extraocular muscle infiltration preceded by evidence of vascular tropism. <i>Journal of Clinical Neuroscience</i> , 2019, 61, 277-278.	1.5	3
22	Impact of adjuvant temozolomide and IDH mutation status among patients with anaplastic astrocytoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2025-2025.	1.6	3
23	Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2061-2061.	1.6	3
24	A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high-grade glioma (Alliance A221101).. <i>Journal of Clinical Oncology</i> , 2020, 38, 12007-12007.	1.6	3
25	ACTR-12. PRELIMINARY SAFETY AND EFFICACY OF A PHASE II TRIAL OF 18F-DOPA PET-GUIDED, DOSE-ESCALATED RADIOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi13-vi13.	1.2	2
26	Phase I/II study of VAL-083 in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2063-2063.	1.6	2
27	Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1) Tj ETQq1 1 0.784314 rgBT /Ov glioblastoma: NCT03532295.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2058-2058.	1.6	2
28	Intrathecal metastases causing conus medullaris syndrome. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 75-75.	0.5	1
29	Evaluation of the Diagnostic Utility of Cerebral Spinal Fluid (CSF) Flow Cytometry (FC) In Detection of Central Nervous System (CNS) Involvement by Hematological Malignancy.. <i>Blood</i> , 2010, 116, 3837-3837.	1.4	1
30	Survival and associated predictors for patients with pineoblastoma or pineal parenchymal tumors of intermediate differentiation older than 3 years: Insights from the National Cancer Database. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	1
31	Index of Suspicion * Case 1: Foot Deformities, Asymmetric Calf Muscles, and Frequent Falls in an 8-year-old Boy * Case 2: Seizures in a 5-month-old Boy Whose Mother Recently Emigrated From Honduras * Case 3: A Gradually Increasing Perianal Mass in a Teenage Girl. <i>Pediatrics in Review</i> , 2011, 32, 163-168.	0.4	0
32	EXTH-15. TESEVATINIB MONOTHERAPY EFFICACY AGAINST GBM12 IS ROBUST IN VITRO BUT RELATIVELY MODEST IN THE INTRACRANIAL GBM12 MODEL, DESPITE EXCELLENT BRAIN PENETRATION. <i>Neuro-Oncology</i> , 2016, 18, vi62-vi62.	1.2	0
33	RARE-53. THE ROLE OF RADIATION AND CHEMOTHERAPY IN ADULT PATIENTS WITH HIGH-GRADE BRAINSTEM GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi233-vi233.	1.2	0
34	MNGI-06. EFFICACY OF 177LU-DOTATATE THERAPY IN RECURRENT ANAPLASTIC MENINGIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi140-vi140.	1.2	0
35	PATH-47. TTF MAY APPLY SELECTIVE PRESSURE TO GLIOBLASTOMA CLONES WITH ANEUPLOIDY: A CASE REPORT. <i>Neuro-Oncology</i> , 2019, 21, vi154-vi154.	1.2	0
36	RARE-37. TREATMENT OF H3K27M MUTANT GLIOMAS WITH PANOBINOSTAT. <i>Neuro-Oncology</i> , 2019, 21, vi229-vi229.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Survival outcomes in patients with early-stage, resectable pancreatic cancer: A comparison of gemcitabine and 5-fluorouracil based chemotherapy and chemoradiation regimens.. Journal of Clinical Oncology, 2012, 30, e14608-e14608.	1.6	0
38	Delineation of MGMT promoter hypermethylation as a predictive biomarker for the A071102 clinical trial of veliparib combined with temozolomide (TMZ) using patient-derived xenograft (PDX) GBM models.. Journal of Clinical Oncology, 2015, 33, 2052-2052.	1.6	0
39	Abstract 3870: The addition of CB-839 to temozolomide significantly reduces glioma aspartate and glutamate in an IDH mutated patient derived glioma xenograft model. , 2019, , .		0
40	KRAS wild-type pancreatic ductal adenocarcinoma: Molecular and therapeutic opportunities.. Journal of Clinical Oncology, 2022, 40, 4130-4130.	1.6	0
41	MET/HGF Coexpression as a Novel Predictive Biomarker for Response to MET Inhibitor Therapy in a Case of Psammomatous Melanotic Schwannoma. JCO Precision Oncology, 2022, , .	3.0	0